498 related articles for article (PubMed ID: 2598478)
21. Effects of a single post-ovulatory dose of RU486 on endometrial maturation in the implantation phase.
Gemzell-Danielsson K; Svalander P; Swahn ML; Johannisson E; Bygdeman M
Hum Reprod; 1994 Dec; 9(12):2398-404. PubMed ID: 7714164
[TBL] [Abstract][Full Text] [Related]
22. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation.
Cameron ST; Critchley HO; Buckley CH; Kelly RW; Baird DT
Fertil Steril; 1997 Jun; 67(6):1046-53. PubMed ID: 9176442
[TBL] [Abstract][Full Text] [Related]
23. The sequence of pituitary responses to synthetic luteinizing hormone releasing hormone (LH-RH) throughout the normal menstrual cycle.
Grimes EM; Thompson IE; Taymor ML
Acta Endocrinol (Copenh); 1975 Aug; 79(4):625-34. PubMed ID: 1098349
[TBL] [Abstract][Full Text] [Related]
24. Absence of chorionic gonadotropin in sera of women who use intrauterine devices.
Segal SJ; Alvarez-Sanchez F; Adejuwon CA; Brache de Mejia V; Leon P; Faundes A
Fertil Steril; 1985 Aug; 44(2):214-8. PubMed ID: 4018277
[TBL] [Abstract][Full Text] [Related]
25. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
[TBL] [Abstract][Full Text] [Related]
26. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
[TBL] [Abstract][Full Text] [Related]
27. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.
Sherman BM; Chapler FK; Crickard K; Wycoff D
J Clin Invest; 1979 Aug; 64(2):398-404. PubMed ID: 110834
[TBL] [Abstract][Full Text] [Related]
28. Effects of long-term low-dose mifepristone on reproductive function in women.
Croxatto HB; Kovács L; Massai R; Resch BA; Fuentealba B; Salvatierra AM; Croxatto HD; Zalányi S; Viski S; Krenács L
Hum Reprod; 1998 Apr; 13(4):793-8. PubMed ID: 9619526
[TBL] [Abstract][Full Text] [Related]
29. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
30. The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 alpha concentrations.
Gemzell-Danielsson K; Hamberg M
Hum Reprod; 1994 Sep; 9(9):1626-30. PubMed ID: 7836511
[TBL] [Abstract][Full Text] [Related]
31. The menstrual cycle in women using an intrauterine device.
Faundes A; Segal SJ; Adejuwon CA; Brache V; Leon P; Alvarez-Sanchez F
Fertil Steril; 1980 Nov; 34(5):427-30. PubMed ID: 7439408
[TBL] [Abstract][Full Text] [Related]
32. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
33. Effect of follicle stimulating hormone or human chorionic gonadotrophin treatment on the production of gonadotrophin surge attenuating factor (GnSAF) during the luteal phase of the human menstrual cycle.
Messinis IE; Lolis D; Zikopoulos K; Milingos S; Kollios G; Seferiadis K; Templeton AA
Clin Endocrinol (Oxf); 1996 Feb; 44(2):169-75. PubMed ID: 8849571
[TBL] [Abstract][Full Text] [Related]
34. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
35. Pregnancy-specific beta 1-glycoprotein and chorionic gonadotropin-like immunoreactivity during the latter half of the cycle in women using intrauterine contraception.
Seppälä M; Rutanen EM; Jalanko H; Lehtovirta P; Stenman UH; Engvall E
J Clin Endocrinol Metab; 1978 Dec; 47(6):1216-9. PubMed ID: 318094
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of ovulation by low-dose mifepristone (RU 486).
Ledger WL; Sweeting VM; Hillier H; Baird DT
Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
[TBL] [Abstract][Full Text] [Related]
37. Response to intermittent RU486 in women.
Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
[TBL] [Abstract][Full Text] [Related]
38. Plasma hormones and pituitary luteinizing hormone in the rat during the early stages of pregnancy and after post-coital treatment with tamoxifen (ICI 46,474).
Watson J; Anderson FB; Alam M; O'Grady JE; Heald PJ
J Endocrinol; 1975 Apr; 65(1):7-17. PubMed ID: 1141814
[TBL] [Abstract][Full Text] [Related]
39. The secretion of human chorionic gonadotropin-like substance in women employing contraceptive measures.
Huang SC; Chen HC; Chen RJ; Hsieh CY; Wei PY; Ouyang PC
J Clin Endocrinol Metab; 1984 Apr; 58(4):646-53. PubMed ID: 6699130
[TBL] [Abstract][Full Text] [Related]
40. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
